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Abstract
Background: Studies carried out during the 1990’s demonstrated the presence of fungal glycoinositol
phosphorylceramides (GIPCs) with unique structures, some of them showed reactivity with sera of patients with
histoplasmosis, paracoccidioidomycosis or aspergillosis. It was also observed that fungal GIPCs were able to inhibit
T lymphocyte proliferation “in vitro”, and studies regarding the importance of these molecules to fungal survival
showed that many species of fungi are vulnerable to inhibitors of sphingolipid biosynthesis.
Results: In this paper, we describe a detailed characterization of an IgG2a monoclonal antibody (mAb), termed
MEST-3, directed to the Paracoccidioides brasiliensis glycolipid antigen Pb-2 (Manpa1®3Manpa1®2IPC). mAb
MEST-3 also recognizes GIPCs bearing the same structure in other fungi. Studies performed on fungal cultures
clearly showed the strong inhibitory activity of MEST-3 on differentiation and colony formation of Paracoccidioides
brasiliensis, Histoplasma capsulatum and Sporothrix schenckii. Similar inhibitory results were observed when these
fungi where incubated with a different mAb, which recognizes GIPCs bearing terminal residues of b-D-
galactofuranose linked to mannose (mAb MEST-1). On the other hand, mAb MEST-2 specifically directed to fungal
glucosylceramide (GlcCer) was able to promote only a weak inhibition on fungal differentiation and colony
formation.
Conclusions: These results strongly suggest that mAbs directed to specific glycosphingolipids are able to interfere
on fungal growth and differentiation. Thus, studies on surface distribution of GIPCs in yeast and mycelium forms of
fungi may yield valuable information regarding the relevance of glycosphingolipids in processes of fungal growth,
morphological transition and infectivity.
Background
Drouhet [1] described the existence of over 72,000 spe-
cies of fungi widespread in nature, and more than 300
may be associated with human mycoses. In the last two
decades, it was observed a dramatic raise in mortality of
immunosupressed individuals associated with fungal
infection. Although antifungal therapies have been suc-
cessful and selective, the outbreaks of resistant strains,
together with an increase on fungal tolerance levels to
currently available antifungal, were described by several
reports [1,2]. Therefore, a compelling search for novel
antifungal therapies has been greatly stimulated. Studies
carried out during the 1990s demonstrated that many
species of fungi are vulnerable to inhibitors of enzymes
of the sphingolipid biosynthesis pathway, such as inosi-
tol phosphorylceramide (IPC) synthase [3,4]. This parti-
cular enzyme transfers myo-inositol-1-phosphate from
phosphatidylinositol to ceramide, the first and an essen-
tial step for the biosynthesis of glycoinositol phosphoryl-
ceramides (GIPCs), a class of complex anionic
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glycosphingolipids (GSLs) widely distributed among fun-
gal species [5-7]. In this manner, GIPCs synthesis are
highly susceptible to IPC synthase inhibitors, which in
turn are remarkably toxic to many mycopathogens, but
exhibit low toxicity in man, since the IPC or IPC-
synthase gene are absent in mammals [5].
The detailed characterization of GIPCs from a variety
of fungi revealed an extensive structural diversity. Based
on further studies, more than 30 distinct GIPC struc-
tures have been identified to date, which may present
one of the 3 well-confirmed core structures distinguish-
able at the monoglycosyl level and absent in mammals
[5-7]. Some of these GIPCs have antigenic glycoside
determinants, such as terminal b-D-galactofuranose resi-
dues, which are recognized by human sera, suggesting
their potential as targets for immunodiagnostic and the
possibility of therapy based on stimulation of mamma-
lian humoral response [8-15]. It should be emphasized
that the expression of these GIPCs is considerably
dependent on species, and at least for some mycopatho-
gens, strongly regulated during morphogenesis
[8-11,13,16-23].
In this context, to investigate the role of GSLs in dif-
ferentiation and colony formation of Paracoccidioides
brasiliensis, Histoplasma capsulatum, and Sporothrix
schenckii, we used three monoclonal antibodies (mAbs)
raised to fungal GSLs: a) mAb MEST-1 directed to
terminal Galfb1®3/6Manp [13], b) mAb MEST-2 direc-
ted to b-glucosylceramide [24], and c) mAb MEST-3
directed to terminal Manpa1®3Manpa1®2Ins (this
work). Table 1 summarizes the reactivity of mAbs
MEST-1, -2 and -3: i) to lipids extracted from yeast and
mycelium forms, which were analyzed by high perfor-
mance thin layer chromatography (HPTLC) immunos-
taining, and ii) to yeast and mycelium forms of fungi
used in this work, that were analyzed by indirect immu-
nofluorescence (IFI). As shown in this paper, the avail-
ability of mAbs specifically directed to different GSL
structures may be used as effective tools to a more
accurate understanding of the organizational pattern
and the biological role of GSLs of different fungi.
Results
Characterization of mAb MEST-3
Aiming to study the biological role of GIPCs, and since
expression of these glycoconjugates with terminal galacto-
furanose residues, which are recognized by MEST-1, is
restricted to P. brasiliensis (Pb), H. capsulatum (Hc) and
A. fumigatus (Af), we decided to develop a mAb directed
to GIPC Pb-2, from P. brasiliensis, which structure Man-
pa1®3Manpa1®2IPC is expressed in a wide variety of
fungi, and therefore a mAb directed to such structure
would be highly desirable to detect a large number of
pathogenic fungi. Among a few clones showing reactivity
with GIPC Pb-2, a clone secreting an IgG2a monoclonal
antibody was established, and termed MEST-3. By
HPTLC-immunostaining (Figure 1B, lanes 1-3) it was
observed that MEST-3 reacts with Pb-2 from yeast and
mycelium forms of P. brasiliensis, and other GIPCs con-
taining the same structure as Pb-2, such as Hc-Y2 from
yeasts of H. capsulatum (Figure 1B, lane 7), Ss-Y2 from
yeasts of S. schenckii (Figure 1B, lane 9), Af-2 from hyphae
of A. fumigatus (Figure 1B, lane 4), and An-2 from hyphae
of A. nidulans (Figure 1B, lane 5). Moreover, lanes 6 and 8
of Figure 1A-B confirm that mycelium forms of H. capsu-
latum and S. schenckii do not express GIPCs bearing the
epitope recognized by MEST-3, as described before
[8,9,22,23]. Also, by solid-phase radioimmunoassay (RIA),
it was verified that mAb MEST-3 was able to detect as low
as 5 ng of purified Pb-2, Hc-Y2, SS-Y2 and Af-2 (Figure
1C). Conversely, no reactivity of MEST-3 with GIPCs, pre-
senting the structures Manp(a1®3) [Galf(b1®6)]Manp
(a1®2)IPC (Pb-3, Hc-Y3, Af-3); Mana1®2IPC (MIPC)
and Mana1®3Mana1®6IPC (Ss-M2), was detected by
HPTLC-immunostaining or RIA.
Treatment of Pb-2 with sodium m-periodate led to a
decrease of 82% of mAb MEST-3 binding to this GIPC,
indicating that MEST-3 recognizes the carbohydrate
moiety of Pb-2 (data not shown), the structural features
of the glycoepitope, recognized by MEST-3, was ana-
lyzed by inhibition assays on solid-phase RIA carried on
96-well plates pre-coated with purified Pb-2 antigen
using different methyl-glycosides, disaccharides and gly-
cosylinositols derived from GIPCs. As shown in Figure
2, methyl-a-D mannopyranoside, Mana1®2Man and
Mana1®6Man did not inhibit MEST-3 binding to Pb-2,
whereas disaccharide Mana1®3Man and glycosylinosi-
tol Mana1®3Mana1®2Ins, at a concentration of 25
Table 1 Reactivity of mAbs MEST-1, -2 and -3, with
different fungi preparation
MEST-1
Galfb1®3/6Manp
MEST-2
GlcCer
MEST-3
Manpa1®3Manpa1®2Ins
HPTLC IFI HPTLC IFI HPTLC IFI
Pb Y + + + + + +
M + - + - + -
Ss Y - (np) - (np) + + + +
M - (np) - (np) + - - (np) - (np)
Hc Y + + + + + +
M - (np) - (np) + - - (np) - (np)
Reactivity of mAbs MEST-1, -2 and -3, with fungal glycolipids by HPTLC
immunostaining (HPTLC); and with fixed fungi by indirect
immunofluorescence (IFI). Pb = P. brasiliensis; Ss = S. schenckii; Hc = H.
capsulatum; Y = yeast; M = mycelium; MEST-1 recognizes epitope Galfb1®3/
6Manp; MEST-2 recognizes fungal glucosylceramide (GlcCer); MEST-3
recognizes epitope Manpa1®3Manpa1®2Ins; “+“ indicates positive staining;
“-“ indicates negative staining, and “np“ indicates epitope not present. [1324].
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mM, were able to inhibit by 80% the binding of MEST-3
to Pb-2 antigen. In addition, glycosylinositol Mana1®3-
Mana1®6Ins, derived from Ss-M2 of mycelium forms
of S. schenckii, was not able to inhibit MEST-3 binding
to Pb-2. Taking together, these data indicate that the
epitope recognized by MEST-3 is not restricted to the
terminal residue of mannose, but also includes the sub-
terminal residues of mannose and myo-inositol (3man-
nosea1®2myo-inositol). Therefore, these results clearly
indicate that MEST-3 recognizes specifically GIPCs pre-
senting the linear structure Manpa1®3Manpa1®2myo-
inositol.
Indirect immunofluorescence with MEST-3
As shown in Figure 3, indirect immunofluorescence
using MEST-3 showed that yeast forms of P. brasiliensis
and H. capsulatum present homogenous surface label-
ing, whereas yeast forms of S. schenckii present an inter-
spersed labeling at cell surface. By HPTLC
immunostaining or RIA, mAb MEST-3 showed
reactivity with GIPCs isolated from mycelium forms of
P. brasiliensis and hyphae of A. fumigatus and A. nidu-
lans (Figure 1A-C), but it is noteworthy that no fluores-
cence was observed with mycelium forms of P.
brasiliensis and hyphae of A. fumigatus and A. nidulans
(not shown). As expected, by immunostaining and RIA
(Figures 1A-C), no reactivity of MEST-3 was observed
with mycelium forms of S. schenckii and H. capsulatum.
Negative controls using an irrelevant mAb showed no
fluorescence (not shown).
Effect of monoclonal antibodies on fungal growth
By counting the total number of colony forming units
(CFUs), the effect of mAbs MEST-1, -2 and -3 at differ-
ent concentrations on fungal growth was analyzed.
Under the conditions described in Methods, it was
determined for P. brasiliensis, H. capsulatum and S.
schenckii, a total of 57 ± 4, 41 ± 3 and 79 ± 4 CFUs,
respectively. As shown in Figure 4A, mAbs MEST-1 and
-3 were effective in inhibiting P. brasiliensis and H.
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Figure 1 Reactivity of fungal GIPCs with MEST-3. Fungal GIPCs were purified by a combination of chromatography in DEAE-Sephadex, silica
gel 60, HPLC and preparative HPTLC. HPTLC was developed in solvent A. Panel A, stained with orcinol/H2SO4 and panel B, immunostaining
with MEST-3. Lane 1, GIPC Pb-2 from mycelium form of P. brasiliensis; lane 2, acidic GSLs from mycelium form of P. brasiliensis; lane 3, acidic GSLs
from yeast form of P. brasiliensis (Pb); lane 4, acidic GSLs from hyphae of A. fumigatus (Af); lane 5, acidic GSLs from hyphae of A. nidulans (An);
lane 6, acidic GSLs from mycelium form of H. capsulatum (Hc); lane 7, acidic GSLs from yeast form of H. capsulatum; lane 8, acidic GSLs from
mycelium form of S. schenckii (Sc); lane 9, acidic GSLs from yeast form of S. schenckii; lane 10, acidic GSLs from the edible mushroom Agaricus
blazei (Ab). Arrows indicates chromatographic migration of Pb-2, Af-2, An-2, Hc-Y2 and Ss-Y2. Panel C, GIPCs (first well 0.1 μg) were serially
double diluted in ethanol and adsorbed on a 96-well plate. MEST-3 (100 μl) was added and incubated overnight at 4°C. The amount of antibody
bound to GSLs was determined by incubation with rabbit anti-mouse IgG (2 h) and 105 cpm of 125I-labeled protein A in 1% BSA. Pb-2 from
yeast (closed square) and from mycelium (closed triangle) forms of P. brasiliensis; Ss-Y2 (open circle) from yeast form of S. schenckii; Af-2 (open
triangle) from A. fumigatus, Hc-Y2 (open inverted triangle) from yeast forms of H. capsulatum, Pb-3 (closed inverted triangle) from yeast and Pb-3
(closed diamond) from mycelium forms of P. brasiliensis and Ss-M2 (open diamond) from mycelium forms of S. schenckii.
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capsulatum CFUs in a dose-dependent manner. mAb
MEST-1 was able to inhibit P. brasiliensis and H. capsu-
latum CFU by about 38% and 45%, respectively, while
MEST-3 inhibited P. brasiliensis, H. capsulatum and S.
schenckii CFUs by about 30%, 55% and 65%, respectively
(*p < 0.05). Conversely, as expected, MEST-1 was not
able to inhibit S. schenckii CFU, since this fungus does
not present glycolipids containing terminal residues of
b-D-galactofuranose [22,23]. It should be noted that
MEST-2 did not present significant CFU inhibitory
activity in none of the three fungi used in this study.
Confirming these results, P. brasiliensis, H. capsulatum
and S. schenckii were grown in media containing mAbs
for 48 h, after that, MTT {3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide} was added to measure
the growth rate. As observed in Figure 4B, MEST-1 and
-3 inhibited significantly the growth of P. brasiliensis
and H. capsulatum, whereas for S. schenckii, only
MEST-3 was able to inhibit fungal growth.
Effect of monoclonal antibodies on fungal dimorphism
In order to analyze the effect of mAbs MEST-1, -2 and
-3 on yeast to mycelium transformation of P. brasilien-
sis, H. capsulatum and S. schenckii, at first, yeast forms
were incubated with these mAbs for 48 h at 25°C,
which is the optimum temperature for mycelia growth.
As observed for CFU, mAbs MEST-1 and -3 were also
able to inhibit in a dose-dependent manner the yeast
to mycelia differentiation of P. brasiliensis and H. cap-
sulatum (Figure 5). In these experiments, 50 μg/ml of
MEST-1 was able to inhibit the conversion of approxi-
mately 50% of P. brasiliensis, and 55% of H. capsula-
tum from yeast to mycelia. Under the same condition,
MEST-1 was not able to inhibit the conversion from
yeast to mycelia in S. schenckii (Figures 5). Moreover,
mAb MEST-3 was able to inhibit the conversion of
yeast to mycelia of approximately 30% of P. brasilien-
sis, 55% for H. capsulatum and 50% for S. schenckii
(Figure 5).
Furthermore, considering the relative proportion of
yeast and mycelia forms as well the hyphal length, it
was verified that mAb MEST-1 (Figure 6) and MEST-3
(not shown) were able to inhibit P. brasiliensis and H.
capsulatum yeast to mycelia differentiation as early as
24 h after mAb incubation. Additionally, only MEST-3
(Figure 6) was able to inhibit S. schenckii yeast to myce-
lium differentiation. In contrast, no inhibition of yeast
to mycelium differentiation was observed upon incuba-
tion of these fungal species with MEST-2 (Figure 5).
Parallel experiments showed that after washing and
replacing medium containing mAbs by antibody-free
medium; the fungi tested were able to restore their
growth and/or transformation, indicating that mAbs
MEST-1, -2 and -3 present a fungistatic effect (data not
shown).
In another set of experiments, it was evaluated the
effect of mAb MEST-1 and -3 on P. brasiliensis myce-
lium to yeast transformations, and as expected, it was
not observed a significant inhibition, since these antibo-
dies do not react or react weakly with mycelium forms.
Thus, 50 μg/ml of MEST-1 and MEST-3 inhibited,
respectively, 6% and 9% the transition from mycelium to
yeast of P. brasiliensis. Figure 7 shows the differentiation
of P. brasiliensis mycelia forms grown in presence
(Panel B) or not (Panel A) of MEST-3 for 48 h at 37°C.
In order to illustrate the differentiation inhibition, but
not picturing the real inhibition percentage, Figure 7B
pictured a field with high concentration of hyphae form.
Discussion
mAb MEST-3 specificity
In this paper, we describe the characterization of MEST-
3, an IgG2a monoclonal antibody directed to the struc-
ture (Manpa1®3Manpa1®2IPC) from GIPC Pb-2 of P.
brasiliensis. Among different methyl-glycosides, disac-
charides and glycosylinositols, only Manpa1®3Manp
and Manpa1®3Manpa1®2Ins inhibited MEST-3 bind-
ing to Pb-2 in solid-phase RIA. Furthermore, MEST-3
was unable to recognize, by solid-phase RIA or HPTLC-
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Figure 2 Inhibition of mAb MEST-3 binding to Pb-2. 96-well
plates were adsorbed with GIPC Pb-2 from mycelium forms of P.
brasiliensis. Methyl-glycosides, disaccharides and GIPC-derived
glycosylinositols (first well 100 mM) were serially double diluted
with PBS and preincubated with MEST-3, and the inhibition assay
was carried out as described in Materials and Methods. The effects
of the methyl-glycosides, disaccharides and glycosylinositols are
expressed as percentages of inhibition of MEST-3 binding to Pb-2.
(closed square) Manpa1®2Manp, (closed circle) Manpa1®3Manp,
(closed triangle) Manpa1®6Man, (open diamond) methyl-a/b-D-
glucopyranoside; (open circle) methyl-a/b-D-galactopyranoside;
(open triangle) methyl-a/b-D-mannopyranoside, (closed diamond)
Mana1®3Mana1®2Ins, (open square) Mana1®3Mana1®6Ins.
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immunostaining, the intact GIPC Ss-M2 (Manpa1®3-
Manpa1®6IPC), thus suggesting that a1®6 linkage of
the subterminal mannose unit to inositol represents a
sterical hindrance for antigen recognition by MEST-3.
Therefore, the minimum epitope required for optimum
binding of MEST-3 to Pb-2 and similar GIPCs, would
comprise the two linear mannose residues in specific
linkage and the myo-inositol residue as follows:
Manpa1®3Manpa1®2Ins.
By indirect immunofluorescence, it was observed that
MEST-3 is reactive only with yeast forms of P. brasilien-
sis, H. capsulatum and S. schenckii, which is in agree-
ment with previous data describing the crypticity of
GIPC Pb-3 and GlcCer in mycelium forms of P. brasi-
liensis [13,24]. Accordingly, despite the detection of the
GIPC Pb-2 extracted from hyphae of P. brasiliensis by
HPTLC and HPTLC immunostaining with mAb MEST-
3, it should be noted the complete lack of MEST-3 reac-
tivity by immunofluorescence with fixed mycelia forms.
Taking together, these data suggest that a particular
organization of GSLs and/or cell wall structure, distinct
from that found in yeast forms, is required for mAb
MEST-3 binding to fungal GIPC Pb-2. In this context,
the access of antibodies directed to GSLs of mycelium
forms seems to be strongly affected by organizational or
structural aspects that do not favor the interaction anti-
gen-antibody.
Growth and dimorphism inhibition by anti-
glycosphingolipid mAbs
There are several reports in the literature showing the
importance of neutral glycosphingolipids, such as cere-
brosides, on fungal growth and morphological transition
[25-27]. Rodrigues et al. [28] described that the addition
of purified human antibodies, directed to GlcCer from
Cryptococcus neoformans, inhibited cell budding and
growth of this fungus. Therefore, the effects of three
mAbs (MEST-1, -2 and -3), directed to different fungal
GSLs, were analyzed on colony formation (CFU) of
pathogenic dimorphic fungi (P. brasiliensis, H. capsula-
tum and S. schenckii). Experiments using mAb MEST-2,
directed to fungal GlcCer, showed no significant inhibi-
tion of CFU or effect in dimorphism of the fungi stu-
died. These data do not corroborate the results from
Rodrigues et al. [28]. Possible explanations for these
results may be related to the source of the antibodies,
human and murine, in our case, or fungal species, since
this effect was only observed in C. neoformans.
Our results using mAb MEST-1, directed to Pb-3 and
Hc-Y3, showed significant inhibition of fungal growth
and differentiation of P. brasiliensis and H. capsulatum
from yeast to mycelia. As expected, no inhibition with
MEST-1 was observed for S. schenckii, since this specie
does not express galactofuranose-bearing GSLs. On the
other hand, MEST-3 was able to inhibit CFU, fungal
growth and differentiation of all three fungi studied.
MEST-3 was able to cause higher inhibition of CFU and
differentiation for H. capsulatum and S. schenckii than
for P. brasiliensis. This lower degree of inhibition
showed by P. brasiliensis could be attributed to the low
GIPC Pb-2 concentration in yeast forms of this fungus
[10]. On the other hand, GIPCs Hc-Y2 and Ss-Y2,
which bear the same structure as Pb-2, represent about
30% and 20% of acidic glycolipid fraction from H. capsu-
latum and S. schenckii yeast forms respectively [8,23].
Conversely, results observed in the mycelium to yeast
transformation, were not straightforward, a possible
explanation could be related to the non-reactivity of
mAbs MEST-1, -2 and -3, with mycelia forms, as
observed by immunofluorescence assay (Table 1). More-
over, in H. capsulatum and S. schenckii, the transforma-
tion of mycelium to yeast takes at least three weeks in
A B
Hc
Pb
Ss
10 m
Figure 3 Indirect immunofluorescence. Indirect immunofluorescence
of yeast forms of P. brasiliensis (Pb), H capsulatum (Hc) and S. schenckii
(Ss), with mAb MEST-3. A- fluorescence. B- phase contrast.
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Figure 4 Effect of monoclonal antibodies on fungal growth. Panel A, Yeast forms of P. brasiliensis, H. capsulatum and S. schenckii were
incubated for 24 h with mAbs, or a control IgG or left alone, at 37°C. Yeasts were transferred to a petri dish containing PGY or BHI-agar
medium, and incubated for 2 days at 37°C. Colony forming units (CFUs) were counted, and expressed as percentage of those incubated with an
irrelevant mAb, considered as 100% of CFU. Panel B, MTT assay of fungi after incubation with mAbs MEST-1, -2, and -3. Yeast forms of P.
brasiliensis, H. capsulatum and S. schenckii were incubated with mAbs, a control IgG or left alone. After incubation for 48 h, MTT solution was
added to each well and was further incubated for 3 h at 37°C. The absorption was measured at 580 nm. MEST-1 (closed square), MEST-2 (closed
circle) and MEST-3 (closed triangle). * p < 0.05.
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normal conditions, and the mycelium web hinders clear
yeast observation and quantification.
It is now well established that the precise build up of
lipid rafts is necessary to efficiently guide signal trans-
duction through cell membrane [29], some new evi-
dences indicate that in fungi, these constructions are
also necessary for fungal survival and maintenance of
the infection [30]. Two attractive hypotheses for the
inhibitory activity of mAbs MEST-1 and MEST-3 on the
yeast growth and differentiation would be: i) the associa-
tion mAb-GIPCs sterically inhibits the formation of
functional glycosphingolipid-enriched microdomains
(GEM), thus blocking the action of key enzymes respon-
sible for cell wall synthesis [31], and ii) an already exist-
ing microdomain to which a mAb-GIPC association
takes place is not functional, hindering essential signal
transduction to fungal growth and/or dimorphism. Con-
focal microscopy, with P. brasiliensis cell wall stained
with calcofluor white indicates two places of MEST-3
binding, i) extensive and internal to calcofluor labeling,
i.e. plasma membrane, and ii) discrete external as well
as co-labeling with calcofluor, these preliminary data led
us to suggest a new conceptual model of GSL arrange-
ments in yeast forms where microdomain-like regions
containing GIPCs could also be located at the external
surface of the cell wall. Further work to substantiate this
concept model is under investigation in our laboratory
aiming an extensive comprehension of fungal glyco-
sphingolipid enriched microdomains regarding their
composition, surface localization, role in signaling pro-
cesses and possible role in host cell binding and
infection.
This study and others have shown that specific GIPCs
are found in a large variety of pathogenic fungi [6,7]. In
some cases, those GIPCs are recognized by sera from
patients with paracoccidioidomycosis, histoplasmosis or
aspergillosis [8-10,13-15,32], indicating that GIPCs are
immunogenic and able to induce the production of
human antibodies during fungal infections. The broad
distribution of GIPCs in pathogenic fungi and the anti-
fungal activity of monoclonal antibodies directed to
GIPCs indicate that these molecules may represent
potential targets for the development of new therapeuti-
cal approaches based on induction of protective
antibodies.
Conclusion
The fine specificity of MEST-3 was assessed by inhibi-
tion assays using different methyl-glycosides, disacchar-
ides and oligosaccharides. Only Mana1®3Man and the
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Figure 5 Effect of monoclonal antibodies on yeast to mycelium transformation. Yeast forms of P. brasiliensis, H. capsulatum and S. schenckii
were incubated for one hour with different concentration of MEST-1, -2 and -3, and control IgG at 37°C. After that the yeast cultures were
transferred to a 25°C incubator, and kept for 2 days. Three hundred yeasts were counted, and the number of yeast showing hyphae growth was
evaluated. In control experiment 100% of yeast showed hyphae formation; the results represent the percentage of those incubated with an
irrelevant mAb, considered as 100% of yeast to mycelium transformation. MEST-1 (closed square), MEST-2 (closed circle) and MEST-3 (closed
triangle). * p < 0.05.
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glycoinositol Mana1®3Mana1®2Ins, from Pb-2, were
able to inhibit, by about 95%, MEST-3 binding to Pb-2
antigen of P. brasiliensis. The epitope recognized by
MEST-3 was defined as Mana1®3Mana1®2Ins; this
structure was already described in a variety of patho-
genic fungi [5-11,15-17,19,23]. Studies using mAbs
MEST-3 and MEST-1, as fungal growth inhibitors
showed that anti-GIPCs mAbs presented a strong
inhibitory activity on growth, differentiation and colony
formation of P. brasiliensis, H. capsulatum, and S.
schenckii. On the other hand, no statistically significant
inhibition was observed with anti-GlcCer (MEST-2).
These results strongly suggest that mAbs directed to
particular glycosphingolipids are able to interfere on
fungal growth and differentiation. An attractive hypoth-
esis is that, by hindering the formation of functional
Control       MEST-1
P. brasiliensis
0h  
24hs
48hs
Control      MEST-1
H. capsulatum
Control       MEST-3
S. schenckii
10 m 10 m
10 m 10 m
10 m
10 m
10 m10 m
10 m 10 m
10 m 10 m
10 m10 m
10 m 10 m
10 m
10 m
Figure 6 Effect of mAbs on mycelia formation. Yeasts were suspended in 1 ml of PGY or BHI medium. This suspension was added to a 24-
well plate and supplemented with mAb MEST-1 or -3 (50 μg/ml), after one hour at 37°C cells were placed at 25°C. After 24 and 48 h of
incubation yeast differentiation into mycelia forms was observed in an inverted microscope. Controls experiments were performed identically in
presence of irrelevant immunoglobulins (normal mouse total Ig).
B CA
Figure 7 Effect of mAb MEST-3 on yeast formation. P. brasiliensis hyphae fragments were suspended in 1 ml of PGY medium and
supplemented or not with mAb MEST-3 (50 μg/ml). Cells were placed on a 24-well plate at 37°C, and after 96 h of incubation, hyphae
differentiation into yeast (M®Y) forms was observed under microscope. Panel A shows M®Y differentiation in free-mAb medium, Panel B
shows M®Y differentiation in medium containing MEST-3, and Panel C shows the mycelia growth of hyphae fragments maintained at 23°C for
96 h in free-mAb medium.
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lipid rafts by association with mAbs, a possible depen-
dence of surface organization of glycosphingolipids in
fungi is essential for different fungal processes, such as
growth, morphological transition, and infectivity.
Methods
Fungal isolates and growth conditions
Paracoccidioides brasiliensis strain Pb18 was provided by
Dr Z.P. Camargo, São Paulo, SP, Brazil. Yeast and myce-
lia forms of P. brasiliensis were grown at 37°C and 25°C,
respectively, in PGY (peptone 5 g/L, glucose 15 g/L,
yeast extract 5 g/L) using 2.5 L Fernbach flasks in a sha-
ker at 100 rpm [10]. Histoplasma capsulatum strain 496
from human pulmonary lesion [33] and Sporothrix
schenckii strain 65 from human foot cutaneous lesion
[22,23], were kindly provided by Dr O. Gompertz, São
Paulo, SP, Brazil. Yeast and mycelia forms of both fungi
were grown in Brain Heart Infusion (BHI) (37 g/L) at
37°C and 25°C, respectively. After 5-7 days both yeast
and mycelia forms of the various fungi were inactivated
with 0.1% of thimerosal, and after an additional 48 h the
fungi were collected by filtration on Whatman n° 1 filter
paper, except for yeast forms of S. schenckii and H. cap-
sulatum, which were harvested by centrifugation at
5,200 × g for 20 minutes.
Extraction and purification of glycosphingolipids (GSLs)
GSLs were extracted by homogenizing yeast or mycelia
forms (~ 30 g) in an Omni-mixer (Sorvall Inc. Wilming-
ton, DE), three times with 200 ml of isopropanol/hex-
ane/water (IHW, 55:20:25, v/v/v, upper phase
discarded), and twice with 200 ml of chloroform/metha-
nol (CM, 2:1, v/v). The five extracts were pooled, dried
on rotary evaporator, dialyzed against water and lyophi-
lized. Neutral and acidic GSLs were separated in a
DEAE-Sephadex A-25 column as described by Yu and
Ledeen [34]. Fractions containing GIPCs, were assessed
by HPTLC on silica gel 60 plates (E. Merck, Darmstadt,
Germany) using solvent A: chloroform/methanol/CaCl2
0.02%, (60:40:9; v/v/v), and stained with orcinol/H2SO4.
For preparative-scale HPTLC separated GSL bands were
visualized under UV light after spraying with primulin
0.01% in 80% aqueous acetone [35]. GSLs were isolated
from silica gel scraped from the plates by repeated soni-
cation in IHW, as described [36].
Production of hybridomas
About 600 μg of GIPC Pb-2 purified from mycelia forms
of P. brasiliensis were dissolved in 1.5 ml of distilled
water and mixed with 1.5 mg of acid-treated heat-inacti-
vated Salmonella minnesota. Aliquots (100 μl) of this
suspension containing 40 μg of the antigen were used to
immunize six weeks old BALB/c mice, by i.v. route,
through the caudal vein once a week, over 4 weeks.
After a rest period of 30 days, the immune response was
boosted with 200 μl of the immunogenic complex.
Three days later, the mice were sacrificed and their
spleen removed. The lymphocytes were fused with NS-1
myeloma cells and placed in 96-well plates. Solid-phase
RIA detected hybrids secreting immunoglobulins react-
ing with Pb-2. Only clones showing strong reactivity
with Pb-2 of mycelia and yeast forms of P. brasiliensis
were cloned by limited dilution as described [13,24,37].
Research ethical approval (CEP 0023/06) was granted by
the Ethical Research Committee Boards of Universidade
Federal de São Paulo.
Binding assay
Various GSLs were adsorbed on 96-well plates (Falcon
Microtest III flexible assay plates, Oxnard, CA). Solu-
tions (25 μl/well, 100 ng/first well) in ethanol of differ-
ent GSLs were serially diluted, dried at 37°C and wells
blocked with 1% bovine serum albumin (BSA) in 0.01 M
phosphate-buffered saline (PBS), pH 7.2 (200 μl) for 2 h,
and sequentially incubated with mAb MEST-3 (100 μl)
overnight at 4°C, rabbit anti-mouse IgG (50 μl) for 2 h,
and with 50 μl of 125I-labeled protein A in PBS with 1%
of BSA (about 105 cpm/well) for 1 h. The amount of
mAb MEST-3 bound to Pb-2 was determined by mea-
suring the radioactivity in each well in a gamma counter
[13].
Release of glycosylinositols by ammonolysis
Ammonolysis of GIPCs was performed as described by
Barr and Lester [8] and Levery et al. [11]. Briefly, 100
μg of GIPCs Pb-2 and Ss-Y2 were heated in a Teflon-
lined screw-capped test tube with 10 N NH3.H20 (~ 1
mL) for 18 h at 150°C. The solution was cooled and
evaporated under N2 stream at 37°C; this process was
repeated after addition of a few drops of 2-propanol.
The residue was sonicated in 1 mL of water and the
lipophilic components were removed by passage of this
solution through a small C18-silica solid-phase extrac-
tion cartridge, washing twice with 1 ml of water. The
combined aqueous fraction containing free glycosylinosi-
tol was lyophilized and used for inhibition of antibody
binding to GIPCs Pb-2.
Inhibition of antibody binding by different methyl
glycosides, disaccharides and glycosylinositols
Initially, 75 μl of a 200 mM solution of several methyl-
a- and b-D-glycosides (glucopyranoside, galactopyrano-
side and mannopyranoside), disaccharides (Mana1®2-
Man, Mana1®3Man and Mana1®6Man), purchased
from Sigma (MO, USA), and the glycosylinositols (Man-
a1®3Mana1®2Ins and Mana1®3Mana1®6Ins,
described above), were serially diluted with PBS in a 96-
well plate. Each glycoside solution was incubated with
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75 μl of MEST-3 at room temperature [35]. After 2 h,
aliquots of 100 μl were taken and incubated overnight
at 4°C in 96-well plates pre-coated with the GIPC Pb-2
(100 ng/well) essentially as described under Binding
assay.
Periodate oxidation
Ninety-six-well plates were coated with different con-
centrations (100 ng to 5 pg) of GIPC Pb-2 and treated
with 5 and 20 mM of sodium m-periodate in PBS (0.1
M, pH 7.0) at room temperature for 30 min [13]. The
plates were washed with PBS, reduced with NaBH4 (50
mM in PBS) during 30 min, blocked with 5% of BSA in
PBS for 1 h, and incubated overnight with mAb MEST-
3, and processed as described in Binding Assay.
High performance thin layer chromatography (HPTLC)
immunostaining
GIPCs purified from different fungi were separated by
HPTLC, and the immunostaining of the plates was per-
formed by the procedure of Magnani et al. [38], modified
by Zuolo et al. [39] and Takahashi et al. [40]. GSLs (3
μg) were separated in solvent A: C:M:CaCl2 0.02%
(60:40:9; v/v/v), after development, the plates were dried,
soaked in 0.5% polymethacrylate in hexane, dried, and
blocked for 2 h with 1% of BSA in PBS. Plates were then
incubated with mAb MEST-3 overnight followed by
sequential incubations with rabbit anti-mouse IgG and
125I-labeled protein A (2 × 107 cpm/50 ml of BSA/PBS).
Indirect immunofluorescence
Fungi were fixed with 1% formaldehyde in PBS for 10
min. Cells were washed, suspended in 1 ml of PBS, and
20 μl of the solution was added to a coverslip pre-trea-
ted with poly-L-lysine 0.1% during 1 h. Air dried pre-
parations were soaked for 1 h in PBS containing 5% of
BSA, and incubated subsequently with culture superna-
tant of mAb MEST-3 (2 h), biotin-conjugated goat anti-
mouse IgG (1 h), and with avidin-conjugated fluorescein
(1 h). After each incubation the coverslips were washed
five times with PBS. The coverslips were examined with
an epifluorescence microscope [13]. Control experi-
ments for each fungus were carried out, in the presence
of an irrelevant monoclonal antibody, and no fluores-
cence was observed.
Cell growth
To evaluate the influence of mAbs directed to GSLs on
the growth of different fungi, yeasts (104/ml) were incu-
bated in 96-well plate in the presence of mAbs MEST-1,
-2, or -3 for 24 h at 37°C, in concentration ranging from
2.5 to 50 μg/ml. The growth rate was evaluated by two
procedures; 1) viable CFU were evaluated by plating 100
μl of the samples onto BHI or PGY agar plates, followed
by incubation for 2 days at 37°C, and colony counting;
or 2) 5 μl of 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide (MTT) solution (5 mg/ml MTT in
phosphate-buffered saline, pH 7,4) were added to each
well and the plates were further incubated at 37°C, for 3
h, after incubation the medium containing MTT was
partially removed, and dimethyl sulfoxide (100 μl) was
added to solubilize the MTT formazan product [41].
The absorbance of each well was measured at 580 nm
by a microtiter ELISA plate reader. Control systems
were similarly treated with an irrelevant immunoglobu-
lin (normal mouse total Ig) and plated. All experiments
were repeated three times in triplicates, and the results
shown are a representative of these experiments.
Fungal differentiation - yeast to mycelium
104 viable yeasts were suspended in 1 ml of PGY (P.
brasiliensis) or BHI (H. capsulatum and S. schenckii)
medium. The suspension was incubated in a 24-well
plate and supplemented with mAb MEST-1, -2, or -3 (at
a concentration of 2.5, 10, 25 or 50 μg/ml), after one
hour at 37°C, 24-well plate was transferred to a 24°C
incubator and kept for 2 days. The number of yeast
showing hyphae growth was counted, and presented as
percentage of those incubated with irrelevant immuno-
globulins (normal mouse total Ig). In control experiment
100% of yeast showed hyphae formation. For each mAb
concentration, 300 viable fungi (yeast or transforming-
yeast) were counted, yeasts differentiating into mycelia
forms were observed and evaluated considering hyphae
formation. Control experiments were performed identi-
cally, with the addition of irrelevant immunoglobulins.
Experiments were performed in triplicate sets and repre-
sentative results are shown in Figure 5.
Fungal differentiation - mycelium to yeast
A 5 days old culture containing hyphae, was washed and
combined in a tube with sterile PBS and 5 mm glass
beads, this suspension was agitated in vortex (3 × 5 min),
to broke the web mycelia in small hyphae. After decanta-
tion, the supernatant containing short lengths of hyphae
was centrifuged and the hyphae suspended in 1 ml of
PGY medium. The suspension was incubated in a 24-well
plate and supplemented with mAb MEST-1, -2, or -3 (at
a concentration of 2.5, 10, 25 or 50 μg/ml), at 37°C. After
48 h and 96 h of incubation cultures were analyzed
under inverted microscopy. Controls experiments were
performed identically, with the substitution of mAb to
irrelevant immunoglobulins (normal mouse total Ig).
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